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Background: The use ofPI in HIV-infected patients has been associated with
a variety of metabolic abnormalities.
Methods: This cross-sectional study was undertaken to determine the
prevalence of lipid profile abnormalities in HIV-infected patients treated
with protease inhibitors (PI). All the patients were evaluated with anthro-
pometric measures, a complete hormonal profile, and a lipid profile includ-
ing total cholesterol (Chol), triglycerides, LDL-Chol, VLDL-Chol, HDt-
Chol, apolipoprotein A and B, glucose and insulin.
Results: One hundred and twenty men and 39 women with a mean age of
38.7 ± 8.6 ye:trs were studied. The mean time on PI therapy was 11.7 ± 5.8
months. Most of them (107,69%) were on indinavir. Only 9 patients had
clinical features of Iypodystrophy. Most patients (103, 64.8%) had unde-
tectable levels of viremia. The waist-hip ratio (WHR) was increased in 18
men (15%) and 11 women (28.2%). Abnormal increases of Chol were
present in 36 patients (22.6%), TG in 57 (35.8%), LDL-Chol in 31 (19.6%),
VLDL-Chol in 31 (19.6%), whereas decreases in HDL-Chol were found in
49.6% of men and 56.4% of women. Apo B was incre:tsed in 28.9% of
women, and 34.2% of men. Overall, 14 women (35.9%) and 23 men
(19.2%) had all the lipid parameters within the normal range (p = .05).
There was a positive correlation between WHR and TG level (r = .18, P =
.02), HDL-Chol (r = .32, P = .0001), and VLDL-Chol (r = .2, P = .01).
Conclusions: Protease-inhibitor therapy in HIV-infected patients is asso-
ciated with central obesity and a highly atherogenic lipid profile.
[Mo061 Stevens-Johnson syndrome induced by nevirapine:
Report of 2 cases
A. Mahr', T. Girad2,]. Michot3, M. Robine:tul , O. Lortholary'
t Hopitaux A,'im,"e; 2A. Biclrre; JSaillt-AllloiPle, Assistallce Publique -
Hopitaux de Paris, Bobigny, France
Background: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis
(TEN), and the SJS/TEN overlap syndrome (OS) are severe skin drug
reactions. We report 2 cases ofSJS induced by nevirapine (NVP).
Case reports: A SJS was diagnosed in a 39-year-old HIV-I infected man
(CD 4 = 81{mm3, viral load = 270,OOO{ml) 47 days after the initiation of
NVP, zidovudine and lamivudine. Medication withdrawal resulted in full
recovery, and reexposure with zidovudine, lamivudine and efavirenz was
well tolerated. In a 34-year-old HIV-1 infected man (CD4 = 150/mm3, viral
load = 10,OOO/ml) a SJS occurred 17 days after treatment onset with NVP,
lamivudine and zidovudine. The lesions resolved after treatment disconti-
nuation and administration of intravenous immunoglobulins. No relapse
was observed after reehallenging with zidovudine, lamivudine and indina-
vir.
Discussion: According to a MedIine rese:trch, only 4 eases of NVP-asso-
ciated SJS, TEN, or OS have been published. in clinical trials, NVP-induced
severe skin reactions occurred with a frequency of0.3%, and the incidence
estimated by the French Postmarketing Registry (Boehringer ingelheim
Pharmaceuticals) is 0.03%.
Condusion: Although rare, severe NVP-induced skin drag reactions may
occur even several weeks after treatment onset; the safety of the subsequent
use ofan alternative NNRn, as suggested by one ofour cases, needs further
confirmation.
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[MoP1! Highly active antiretroviral therapy (HAARI'}-induced
metabolic abnormalities in HIV-lnfected patients
cholesterol and tryglyceride variation profile between two groups. The
virologic improvement ofthe subgroups ofpatients with high viral load was
similar in A and B arms. Opportunistic infections were: Arm A: 1 Kaposi's
sarcoma; group B: 2 Kaposi's sarcoma, 1 herpes zoster, I B limphoma.
Changes of treatment due to toxicity: 4 eases: 1 lactic acidosis (d4T), 1
polyneurophaty (ddI), 1 vomiting (IDV), 1 ALT/AST elevation (NVP).
Condusions: The virological and immunological efficacy was similar in
both groups. Both treatment regimens were well-tolerated, with little
repercussion in the patients' lipid profile. No differences were observed in
high viral load subgroups.
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occurring during treatment with protease inhibitors (PI) and unresponsive to
a hypolipidemic diet, received bezafibrate, 400 mg/day.
Results: 49 consecutive p out of ",,800 (6.1%) treated with PI since 2:9
months developed hypertriglyceridemia, with or without concurrent
hypercholesterolemia and hyperglycemia. Twenty-three p received ritona-
vir, 20 indinavir, and the remaining 6 p two combined or sequential PI, for a
mean period of12.9 ± 2.7 months. At the start ofbezafibrate treatment, no
significant difference of mean plasma triglyceride and cholesterol levels,
concurrent signs of lipodystrophy (found in 27 pl. and concomitant fasting
hyperglycemia (found in 9 p), were observed according to prior PI
treatment. Bezafibrate was administered for 2:6 months (and up to 15
months) and led to a reduction oftriglyceride and cholesterollevcls > 40%
and> 25% ofrespective baseline values, already obtained after the 6 months
(p < .(01), and maintained during the subsequent 6 months without
relevant modifications. Thirty-one p of 49 (63.3%) reached normal trigly-
ceride values « 172 mg/dL) after 6-9 months, and normal cholesterol and
glucose levels were obtained in all P with previously detected abnormalities,
while no relevant change of lipodystrophy was observed. No difference of
theupeuric response was detected during the follow-up according to the
underlying PI regimen, but in 4 P treated with ritonavir the persistence of
triglyeeridemia > 300 mg/dL beyond 6 months ofbezafibrate therapy, and
some concurrent drug-related ganrointestinal complaints, made PI switch
necessary. Bezafibrate, had a favorable tolerability profile: mild gastroen-
teric signs and symptoms were found in only 8.2% of 49 p.
Discussion: Metabolic abnormalities are increasingly found among HIV-
infected p receiving PI-containing anti-HIV therapy. so that frequent
monitoring of triglyceride and cholesterol levels is strongly recommended,
in order to provide dietary suggestions and hypolipidemic treatment. By
acting on hepatic synthesis of triglycerides and cholesterol, bezafibrate
demonstrates favorable efficacy and safety in the treatment of PI-related
lipemia.
IMoosl A open-label, randomized, comparative study of
Stavudine (d4l) + Oidan05ine (ddl) + Indlnavir (lOY) versus d4T +
ddl + Nevirapine (NVP) in treatment of HIV-infected naive
patients
]. M. Guardiola, P. Domingo, M. Sambeat. M. Fuste.]. Cadafalch,]. Ris,
]. Barrio. M. Gurgui, G. Vazquez
Sallt Pau Hospital, Barcelolla, Spaill
Objectives: The aim of the study was to find a more eFonomical, better
tolerated and more easily administered therapy with a combination of two
NRTI's with NVP.
Methods: A 32 week randomized study comparing the safety and activity of
d4T 40 mg ql2h + ddl400 mg q24h + NVP 200 mg q12h (arm A) vs d4T
+ ddI + mv 800 mg q8h (arm B) in 50 HIV-infected adults (73% males,
mean age 39.3 ± 17.8 years) who were treatment naIve with HIV RNA>
5000 copies/mL (Amplicor, Roche assay). The primary endpoints were
percentage ofpatients with < 200 and < 50 cp/mL HIV RNA, change from
baseline in plasma HIV RNA and CD4 cell count. Lipidic profiles and the
incidence of clinical events and treatment toxicity was analyzed. Moreover
we analyze a subgroup ofpatients with high viral load (> 100.000 cop/mL).
Results: Median entry HIV RNA and CD4 cell count were 5.2 log and 5.4
log; and 370 and 337 c/mm3 for group A (n = 26) and group B (n = 24)
respectively. Intent to treat analyses is: HIV RNA below < 200 cop/mL and
< 50 cop/mL is 72% and 51 %; and 71.3% and 50% for A and B groups
respectively. Changes from baseline in plasma HIV RNA and median
increase of CD4 cells/mm3 count were: -1.9 log and -1.5 log; and 223
and 166 for a A and B group re>pcetivdy. No differences were observed in
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IMoP21 HAARTattack - A case report
M. Cerbu, E. Nicoara
University ofMedicine and Pharmacy, Timi/oara, Romania
Objectives: To analyze the impact ofantiretroviral therapy on the evolution
of Mycobacterium tuberculosis infection .
Methods: We describe a clinical case: a patient with advanced AIDS, with
personal history ofpulmonary tuberculosis. The patient was started on triple
antiretroviral therapy (nucleosidic reverse-transcriptase inhibitor + non-
nucleosidic reverse-transcriptase inhibitor + protease inhibitor), a thera-
peutic regimen known as Highly Active Antiretrov~alTherapy (HA:"R'ry.
Two weeks after the initiation ofHAART, the panent developed dissemi-
nated tuberculosis with lymphatic, splenic, and renal determinations.
Results: The 37-old male patient was diagnosed with advanced AIDS (CD4
count = 138 cells/ml) at the initiation ofHAART. Signs and symptoms at
presentation: fever, weight loss, diarrhea, and generalized lymphadenopa-
thy. Two weeks after the start of HAART, the patient developed le~t
cervical necrotising adenopathy followed by the appearance of a splemc
image withe decreased echogenicity at the ultrasound examination, hepatic
and renal failure. Mycobacterium tuberculosis was isolated from the lymph
node aspirate, peritoneal fluid and urine. The evolution was little influence.d
by the intensive care therapy, with the impossibility to reverse the hepatic
and renal failure.
Conclusion: Mycobacterium tuberculosis infection is reactivated and dissemi-
nates after the initiation ofHAART and can produce multiple organ failure.
IMoP31 Side eects of HAARTat adults
c. S. Lungu, S. Rugina, C. N. Rugina
Municipal Clinical Hospital, Constantza, Romania
Objedlves: To study the clinical and biochemical side effects ofHAARTat
HIV patients (pts).
Methods: 48 HIV pts, that received anti-HIV therapy, were evaluated
between January-October 1999, considering the signs, the symptoms and
the biochemical alterations. 14 of48 pts assumed dual therapy with NRTIs
and 33 were treated with HAART: 10 with NNRTIs containing antire-
troviral regimen and 23 with PIs. .
Results: Side effects were revealed in 23 of33 pts: at 5 of 10 pts treated WIth
NNRTIs, at 18 of23 pts treated with PIs respectively. The following table
shows the most frequent side effects:
Pl- NNRTl- Pl- NNRTl-
Clinical regimen regimen .Biochemical regimen regimen
sideelfects No. No. side effects No. No.
Gastrointestinal 11 Anemia/
symptoms thombocytopenia 4
Renal colic/
renal stones Hepatic cytolysis 2
Lipodystrophy Hyperbilirubinemia 1
Neurological
signs/symptoms 2 Hyperamilasemia 3
Hypertrygliceride-
Rash 2 Mia 7
Hypercholesterole-
mia 7
Hyperglycemia 4
Alopecia Hyperuricemia 3
Conclusions: Our preliminary study showed a high rate of side effects
occurring in pts treated with HAART, especially in PIs containing regimen.
The most frequent side effects are hyperrrygliceridemia and hypercholester-
olemia that like lipodystrophy, indicate metabolic fat abnormalities and
suggest the need of a more careful metabolic follow-up and cardiovascular
surveillance.
IMoP4! Acddental overdose of Ritonavir in patient with HIV
infection
F. Di Candilo, S. Guerrieri, M. Fiorio
Infectious Diseases, University ofPerugia, Italy
Backgroud: The number ofdrugs used and the complexity ofdrug schedule
in HIV patients may contribute to morbidity due to accidental errors.
objective: To describe a case ofacute overdose ofRitonavir (RTV) in HIV
infected-patient treated with HAART.
Case report: A 61 years-old homosexual, known to be HIV-infected since
February 1990, was treated with HAART from September 1997 (D4T, 3TC
and RTV, 600 mg bid). Triple-therapy resulted to be clinically, immuno-
logically and virologically efficacious as CD4 count was 367 cells/mmc
(21 %) and HIV-RNA was undetactable « 400 copies, Amplicor, Roche).
A day he taken, by mistake, 80 ml of R TV oral solution, equivalent to
6400 mg of drug. After two hours drug ingestion,. pat~ent com~laint.~f
tiredness, headache, dry mouth, circumoral paresthesia, dlZzmess, disequili-
brium of gait. No relevant changes of vital signs (pulse and respratory rate,
blood pressure) or oflaboratory values were found except for ECG showing
prolongation ofQT period (0.41 sec.).
All the symptoms and the ECG alterations resolved gradually in 48-72
hours, witout any therapy.
Serum samples to determine plasma concentrations of R TV were
collected hourly over a six hour period.
Conclusion: This case of accidental overdose ofRTV (ten-fold of a single-
dose) suggest that acute toxicity is clinically similar to chronic side-effects
and that ECG alterations are the most prominent feature.
IMopsi Clinical and economic outcomes for HIV+ patients on
dual PI regimens stratified by prior P!-experience
D. Butcherl , S. Mayer2, R. Rode2, R. Slaker3, C. de Guzman3, E.
Hamel3, D. Lapins3
'Chase Brexton Health Services, Inc., Baltimore, MD; 2A bboll Laboratories,
Abbott Park; JClinical Partners, San Francisco, CA, United States
Objective: To determine differences in clinical and cost outcomes for
patients (pts.) on dual PI regimens, based on degree of previous PI-
experience.
Methods: Data from 1,933 pt. charts analyzed for duration of therapy and
viral load (VL). Pts. initiating dual PI regimen between 1/1/96-12/31/913
identified and stratified into PI-naive, 1 previous PI regimen, > 1 previous
PI regimen. Therapy discontinuation defined as change in any PI. For
patients initially unsuppressed (VL > 400), time to first suppression defined
as time elapsed from start of dual Pi regimen to first VL ~ 400. Survival
distribution estimates made using right-censored data: hazard ratio (HR)
calculated using Cox proportional hazards. Utilization and cost of care
determined from claims for a subset of pts.
Results: 341 pts. started on 410 dual PI regimens (104 PI-na'ive, 306 PI-
experienced) and unsuppressed at therapy initiation. Significant differences
found in time to therapy discontinuation (HR = 1.253; P = 0.0001) and
time to suppression (HR = 0.669; P = 0.0001) based on degree ofprevious
PI-experience. Average cost ofcare per patient per month (PPPM) compar-
able for PI-na'ive (N = 49: SI780 PPPM) and one previous PI regimen (N =
68; SI727 PPPM), increased with> 1 previous PI regimen (N = 66; $2,631
PPPM). Average hospital days PPPM 0.066; 0.013: 0.102 respectively.
Conclusions: Dual PI therapy has longer duration and results in shorter time
to suppression for PIna'ive pts. as compared to PI-experienced pts. Utiliza-
tion and cost ofcare increases substantially for dual PI patients exposed to >
1 previous PI regimen. Results suggest dual PI therapy Is more beneficial
when used earlier in patient's course of therapy.
IMoP61 Comparison of HAARTand dual nucleoside
combination therapy (RT) in Upper-Austrian HIV-positive
patients
Angelika Bocksrucker l , Maria Geit2, Christoph Lugerl, Diane
Thompsonl, Sabine Meczl,Josef Aubock2, Helmut Mittermayerl
tDept. ofHygiene, Med. Microbiologie and Tropical Medicine, Elisabethinen
Hospital. Linz; 2HIV/AIDS-Amulatlce, Dept. ofDermatology and
Venerology, AKH Linz, Austria
The main goal ofeach antiretroviral therapy is to improve the quality oflife
and to increase the life expectancy. This is reached through maximal
suppression of the viral replication to allow a reconstitution of the
immune system. But this goal is often failed. We compared th., elf""t of
HAART and R T on the virusload and the CD4-cell count in HIV-positive
patients during a period of 2 years.
Patients and Methods: The study population consists of 187 HIV infected
patients treated at the AKH Lim between May 1996 and May 1998. All the
patients were followed up on average in three monthly intervals.
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[MoP71 Continued Indinavir (IDV)(800 mg tid) vs switching to
IDV + Ritonavir (8001100 mg bid) in HIV patients having
achieved viralload sup- pression: A randomized study. The BID
Ecacy & Safety Trial (BEST)
J. Lundgren!,j. Gerstoft2, D. Podzamczer3, P. Reiss4, D. BurgerS, F.
Antunes6, A. D'Armini07,j. Arnaiz8,j. Gatell8
For the BEST study team; 'CHIP, Hvidovre; 2Rigshospiudet, Copenhagen,
Denmark; JHosp de Bel/vitge, I'Hospitalet; 4N ATEC, Amsterdam; sHos? St
Radbout, Nijmegen, Netherlands; 6Hosp Santa Maria, Lisboa, Portugal; Hosp
L Saao, Milano, Italy; BHosp Clinu, Bartelona, Spai"
Objective To assess switching to indinavir (IDY) 800 mg/ritonavir (RTY)
100 mg bid from standard IOV SOO tid dosing.
Methods: Randomized, open-label, multicenter study testing whether
switching to bid IOV SOO mg + RTV 100 mg (oral solution) provides
equivalent antiviral activity and tolerability to continued IDV SOO mg tid
therapy, in 300 stable HIV infected patients on IOV 800 mg tid containing
triple therapy with HIV-I RNA levels < 500 copies/ml.
Results: By December 1999, 156 patients completed a follow-up ofat least 3
months. Baseline characteristics of both groups were similar. Proportions
(95%CI) ofpatients with plasma HIV-1 RNA < 500 copies/ml at 3 months
arc;
Levels of HIV RNA were measured by PCR using the Amplicor HIV
monitor assay (Hoffmann La Roche, Basel, Switzerland). CD4-cell counts
were measured by flow cytometry (Becton, Dickinson).
Statistical analysis: were made using Two-Sample-t-Test, ANOVA, Krus-
kal Wallis ANOVA, Kaplan Meier estimates and log rank test.
Results and Conclusion: According to the virusload four types ofresponder
could be discriminated:
• complete responder (decrease below the detection limit)
• nonresponder
• transient responder (decrease below the detecrion limit followed by an
increase)
• partial responder (decrease but not below the detection limit)
56% ofthe patients with HAART and only 26% ofthe patients with RT
were complete responder, whereas only 13% of patients with HAART and
33% ofthe patients with RTwere nonresponder. The increase ofCD4-cells
correlated with the virusload. The CD4-cell count increased in 75% of the
complete responder. 60% of the patients with HAART and 34% of the
patients with R T showed an increase of the CD4-ceU count of more than
50%. Besides patients with HAART were faster below the detection limit
than patients with R T.
Intenrion-to-treat
As-treated
tid IDV (n = 71)
90 (81-96)
97 (89-99)
bid IDV{RTV (n = 85)
90 (81-95)
95 (87-99)
hetero/homosexual. HIV Stage: A 8 (7%), B 24 (22%), C 66 (61 %).
Evolution: 4.5 ± 2.5 years (0-11), previous treatment period 45.5 ± 23.6
months (0-107). Number of previous antiretroviral drugs: nucleoside
analogues 3.12 (0-5) protease inhibitors: 1.6 (0-4). Reason for NFV
treatment: salvage therapy 77 (72%), secondary effect 17 (16%), naive
patients 13 (12%). Most usual regimes were: AZT 3TC 28 (26%), d4T
ddl 17 (16%). Basal CD4: 319 ± 196 ml (26-775), basal viral load: 5.3 ±
6.07 log (1.2-7.07), basal triglyceride: 2.29 ± 1.8 mmol!1 (0.62-9.9) basal
cholesterol: 4.81 ± 1.2 mmolfl (3.07-9.38) CD4 increase: 82 ± 178 (256-
668). Viral load decrease: 0.5 log ± 0.9 (-5.6-6.08). After a mean of 11.8
months (2-17) offollow-up: continuing with NFV: 85 (75%). Reason for
NFV withdraw21: 20 (85%) terapeutic faillure, 3 (15%) secondary effects.
Undetectable viral load « 200 cop/ml) was achieved in 58 (55%) patients.
Conclusions: NFV is mainly used as salvage therapy in long-term HIV
patients. Undetectable viral load was achieved in 55% patients after 11
months of treatment. Changes in triglyceride and cholesterol levels were
minimal. NFV appears to be well-tolerated.
IMoP91 HIV population with high viral load: A cross sectional
study
j. M. Guardiol2, N. Margall, M. Piqueras, P. Lisbona, D. Monfort, L.
Vidal, D. Garcia, E. Coma, P. Domingo, M. Gurgui, G. Vazquez
Sanl Pau Hospital, Barcelona, Spain
Objectives: of the Study: To analyze the clinical situation of HIV patients
with a important virological failure and the correlation with your inmuno-
logical status.
Methods: We analyzed all patienst with high viral load (> 100.000 cop/ml,
Amplicor, Roche) in a teaching hospital, from June to December of1999. Is
a cross sectional and logitudinal study.
Results: A total of55/800 (6.8%) patients were analyzed. Mean age 39.4 ±
17.6 years (21-65). 44 (SO%) were male. Risk factor: IDU 25 (46%),
heterosexual 22 (41 %), homosexual 6 (12%). High viral load was due to:
poor compliance 23 (46%), debut VIH 13 (26%), demonstrated resistance to
antiretroviral treatment! 10 (20%). Mean follow-up was 24 weeks. Mean
viral load was 5.S ± 6.1 logs (5.0-6.7). CD41ymphocite count were 268 ±
264 mm3. No treatment was followed in 11 (20%) cases. Different
combinations of HAART were administered in the remaining 44 cases.
An acceptable virological improvement (viral load decrease of 1.5 logs or
indetectable viral load) was achieved in IS/55 (27.2%) patients. Opportu-
nistic infections (01) were observed in 17/55 (30.9%) patients: 9 tuberculosis,
4 Pneumostis cari,,;; pneumonia, 2 Kaposi's sarcoma and 1 cryptococcal
meningiri~. The rre~n("eof01 was correla.ted with .3 mean b.3sallym.phocite
count under 200, and mean basallymphocite count in patients without 01
was 300.4 ± 297 (p = 0.05). The I2ck of virological improvement was
mainly observed in patients with poor treatment adherence (p = 0.004).
Conclusions: The presence of 01 was observed mainly in patients with
immunological failure. Unresolved virological failure was related to poor
treatment compliance.
In this preliminary analysis serious adverse event (AE) rate was 4% in the
tid arm vs 6% in the bid arm. Nephrolithiasis developed in 4% (tid arm) vs
10% (bid arm) leading to treatment discontinuation in 1% vs 4% respec-
tively. More patients discontinued therapy because of AEs in the bid arm
than in the tid arm (15% vs 4%) mostly due to taste disturbances or GI
intolerance to R TV oral solution.
Conclusion: These preliminary data suggest that bid administration oflDV
800 mg + RTV 100 mg is reasonably well tolerated and maintains
comparable viral suppression in HIV-infected patients in comparison with
the standard tid regimen.
IMoPSIThe spectrum of Nelfinavir (NFV)-based regimes in HIV
infected patients
j. M. Guardiola, E. Coma,j. Ris, P. Domingo, M. Gurgui, G. Vazquez
Sam Pau Hospital, Barcelona, Spain
Objectives: To analyze the H1V patient population treated with NFV in our
hospital.
Method: A retrospective study was carried out including the clinical history
ofall patients treated with NFV, for at least two months, between April 98
and October 99 in an urban teaching hospital.
Results: 108/140 patients were included. Eighty (74%) were males. Mean
aBe was 39 ± 8.3 years (20-79). Sixty eight (63%) were ex IOU, 40 (37%)
IMoP10I Presence of HIV-1 viral replication in vitro and
nucleoside analogues mutations in patients with low HIV-1 RNA
levels in plasma
G. Martinez, C. Campelo, A. Merchan, 1. Sarria, R. Cisterna
Study Group ofAntiretroviral Resistance. Dept. of Immunology, Microbiology
and Parasitology, School ofMedicine, Bilbao, Spain
Objectives: To analyze the presence ofHIVp24 antigen in MT-2 culture as a
viral replication marker in HIV-infected subjects and its relationship with
genotypic mutations and viral load.
Methods: 18 plasma samples from HIV-infected patients were inoculated
into MT-2 cell line in order to detect the HIVp24 antigen in the supernatant
through an enzyme immunoassay (Innogenetic) including previously a
centrifugation step. Viremia levels were determined using Amplicor H1V-
I Monitor test (Roche) with a lower limit of quantibility of2oo copies/ml
H1V-I RNA. The presence ofRNA nucleoside analogues mutations (41, SO,
70,74,75, 184,215) was analysed through an hybridization microtiter assay.
Results: HIV-I RNA levels below 200 copies/m1 were detected in 3
patients. All of them presented plasma HIV RNA nucleoside analogues
mutations in codons 70 and 215 alone as well as in combination and a positive
p24 antigen in the MT-2 culture. Among the resting 15 subjects with
detectable viral load, 2 had a negative p24 antigen and harbored drug-
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resistant mutant viruses. Only in 4 cases out of 13 with positive p24 antigen
any genotypic resistance mutation was detected.
Conclusions: in spite of low HIV-l RNA levels in plasma which would
indicate a good response to treatment, the presence of viral strains harbour-
ing nucleoside analogue mutations together with a positive HIVp24 antigen
suggest that the infective capacity persists in these patients. Further studies
are needed to evaluate a possible rebound viral load in these cases.
IMoP111 Maternal zidovudine prophylaxis and HIV-1 vertical
transmission
G. V. Zuccotti, E. D'Auria, C. Cucchi, L. Tegaldo, M. Giovannini
Department ofPaediatrics, San Paolo Hospital, Milan, Italy
ObjectIve: Toa~s the role ofthe maternal zidovudine (ZDV) prophylaxis
in the prevention of mother-to-infant transmission of human immunode-
ficiency virus type 1 (HIV-I).
Methods: Fourty-seven HIV-infected mothers and their infants, born
between January 1997 and August 1999 in our Department, were enrolled
in this prospective study.
All the mothers were given ZDV during pregnancy, according to ACTG
076 regimen. Of the 47 treated women, 37 (78.7%) received ZDV alone
(group A) while the remaining (21.3%) received ZDV plus one or two other
antiretroviral drugs (group B). None of the infants received ZDV prophy-
laxis or other antiretroviral treatments. All infants were formula-fed.
The percentage ofelective caesarean section was respectively 75% in the
group A and 100% in the group B (p = 0.18, Fisher's exact test).
Results: The mother-to-infant transmission rate was 2.7% (95% CI,
1.8%-3.5%) in the group A. No HIV infected infants were observed in
the group B.
Conclusions: These findings suggest that maternal ZDV prophylactic treat-
ment alone may be enough to prevent HIV-I vertical transmission.
IMoP12! Comparison between An monotherapy and
combination antiretroviral regimen: safety and ecacy in
preventing HIV vertical transmission
A. Maccabrunil,l. Pacatil , M. F. Ravagni2, G. Michelone', M. Furione3,
M. Gatti4
IInstitute of Infectious Diseases; 2Dept. ofObstetrics and Gynecology; JInfectiuos
Diseases Research Laboratory; 4Virology Service Pavia, Italy
Objectives: The majority ofseropositive women maintain or begin during
pregnancy the optimal antiretroviral combination regimen for their own
health; only in a few cases monotherapy with AZT, still represents the best
preventive strategy. Aim of our study is to better evaluate the efficacy and
safety of the highly active antiretroviral therapy in comparison with AZT
alone in women and newborns.
Methods: During the years 1997-1999 we followed 44 HIV-infected
pregnant women. 25 of them were treated with AZT alone from the 14'
week of pregnancy. 19 (6 of whom still in pregnancy) received double
NRTI therapy with (8 cases) or without (II cases) one PI. Elective caesarean
delivery has been performed in 17/25 cases in the first group and in 8/12 in
the second group ofwomen. 27/37 newborns received AZT during the first
6 weeks of life.
Results: The main adverse effect of the therapy was anaemia, observed in 71
25 women in the 1st group, in 5/8 women (in double therapy with AZT) in
the 2nd and in 8/27 neonates. No teratogenic effects were found in the
neonates exposed to antiviral drugs from the first trimester of pregnancy.
One baby in the 1st group resulted HIV-infected; no cases of transmission
were observed in the second group.
Conclusion: Our data confirm the role ofhighly active therapy with elective
caesarean delivery in preventing the risk of perinatal HIV infection.
Although we couldn't fmd any severe adverse effect in women or in
newborns, more prolonged studies to assess the safety of combination
regimens are mandatory.
[MOP13J Degradation of 3'azido-3'deoxythymidine (AZT) by
Stenotrophomonas mahophila and other bacteria
H. Kruszewska', U. Chmielowiec2, A. Lipkowske, S. Tyski l
1Drug Institute; 2Pharmaceutical Research Institute; J Institute of Industrial
Chemistry, Warsaw, Poland
Stenotrophomonas maltophila may be etiological agent of sepsis, pneumonia
and urinary tract infections of patients with AIDS. Since the deoxythymi-
dine derivative - 3'azido-3'deoxythymidine (AZT) is still used in the
treatment of AIDS, it was interesting to investigate whether some bacterial
strains are able to degrade AZT at concentration used in the therapy.
It was found that S. maltophila (Wrodaw Culture Collection - PCM 2381)
can degrade AZT at concentration 500 J.tg/ml, which did not influence
bacterial growth. On the contrary, E. coli (ATCC 8739), Lactobaci1lus
acidophilus (Biomed, Krakow Culture Collection), P. aeruginosa (ATCC
15442) were not able to degrade AZT, however this drug at concentration
500 J.tg/ml did not inhibit bacterial growth during 140 h of incubation.
Surprisingly, all but L. acidophilus strains were able to degrade egzogenic
deoxythymidine monophosphate (dTMP). Stenotrophomonas maltophila and
P. aeruginosa hydrolysed deoxythymidine monophosphate to deoxythymi-
dine and than to thymine, whereas in case of E. coli, a considerable
accumulation of deoxythymidine was observed in the end of dTMP
hydrolysis, what indicate different mechanism of this degradation.
This study indicate that S. maltophila infections may lead to decrease the
efficiency of AZT treatment in AIDS patients.
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Objectives: Previously we have demonstrated the existence of three HIV-l
variants responsible for the explosive epidemic among IOUs in the former
USSR. To develop a V3-PEIA for subtyping of HIV-1 sera derived from
IDUs. To determine current proportions of infections due to env genetic
subtypes A and B or AlB recombinants at the main sites of the epidemic in
Russia.
Methods: Two synthetic peptides, PI and P2 (Cheingsong-Popov et al.
1994), were evaluated in an PEIA on 63 HIV-1 IOUs sera for which
genotypes had been determined by sequencing. The sensitivities of PI
(subtype B) and P2 (subtype A) were 87% and 75%, respectively. Specificity
of the assay was 100% for both peptides, with 100% predictive values of a
monoreactive positive test for both peptides.
Results: We have serotyped 401/5561DUs sera in five territories. In Tver'
(n = 345), Nizhniy Novgorod (n = 61), and Rostov-on-Don (n = 72)
regions, and Krasnodar Kray (n = 32) 100% of typable sera were found to
belong to env subtype A. All specimens subtyped in Kaliningrad region (n =
46) belonged to etIV subtype B. However, nucleotide sequencing of the gag
p17-p24 encoding region showed that all 17 independently obtained speci-
mens from Kaliningrad region had gagA genotype and, thus, were recom-
binants.
Conduslons: The results demonstrated a high level ofsubtype homogeneity
at the main sites of the epidemic in Russia. HIV-I genetic subtype A
predominates nowadays. At present time another parental gagBenvB strain
is of minor importance in the rDUs epidemic.
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objective: to evaluate the introduction of subtypes other than B in the
population from Southern Spain.
Patients and Methods: 83 patients infected before 1996 (group I), 14
patients infected after 1996 (group 2) and 15 African immigrants living in
the coast of Almeria (group 3) were studied. Molecular subtyping was by
Heteroduplex Mobility Assay with 700 bp amplificates from the V3-V5
loop ofgp120 of:lCrum RNAurPBMC DNA (when viralluaJ was -<: 1000
copies/ml) and amplificates from reference subtypes (A to H) from NIH
AIDS Reagent Program. PAGE and silver staining was used to evaluate
heteroduplex formation.
Results: Subtype B was at 79/83 (95%) from group I (before 1996), at 12/14
(85%) from group 2 (after 1996), and at 7/15 (47%) African immigrants.
